MX2020008116A - Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). - Google Patents
Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).Info
- Publication number
- MX2020008116A MX2020008116A MX2020008116A MX2020008116A MX2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A MX 2020008116 A MX2020008116 A MX 2020008116A
- Authority
- MX
- Mexico
- Prior art keywords
- ghrelin
- goat
- heterocyclyl
- inhibitors
- acyl transferase
- Prior art date
Links
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 3
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 3
- 241000283707 Capra Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, en donde las variables X, R1, n, p y q se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154828 | 2018-02-02 | ||
| PCT/EP2019/051993 WO2019149659A1 (en) | 2018-02-02 | 2019-01-28 | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008116A true MX2020008116A (es) | 2020-09-25 |
Family
ID=61157053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008116A MX2020008116A (es) | 2018-02-02 | 2019-01-28 | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11319310B2 (es) |
| EP (1) | EP3746450B1 (es) |
| JP (1) | JP7150032B2 (es) |
| KR (1) | KR20200118124A (es) |
| CN (1) | CN111655699B (es) |
| AU (1) | AU2019215709A1 (es) |
| BR (1) | BR112020014320A2 (es) |
| CA (1) | CA3087827A1 (es) |
| CL (1) | CL2020001908A1 (es) |
| CO (1) | CO2020009179A2 (es) |
| CR (1) | CR20200331A (es) |
| EA (1) | EA202091804A1 (es) |
| EC (1) | ECSP20050791A (es) |
| IL (1) | IL276137A (es) |
| JO (1) | JOP20200191A1 (es) |
| MA (1) | MA53074A (es) |
| MX (1) | MX2020008116A (es) |
| PE (1) | PE20210175A1 (es) |
| PH (1) | PH12020551169A1 (es) |
| SG (1) | SG11202006300XA (es) |
| WO (1) | WO2019149659A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61937B1 (sr) * | 2016-08-05 | 2021-07-30 | Boehringer Ingelheim Int | Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat) |
| JOP20200187A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| CN111655700B (zh) | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| CN111630055B (zh) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| PL4153600T3 (pl) | 2020-05-22 | 2024-12-16 | Boehringer Ingelheim International Gmbh | Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu |
| EP4153599B1 (en) * | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| PL2370462T3 (pl) | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| AU2008365557A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20130086343A (ko) | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| US9238639B2 (en) | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| WO2016123275A1 (en) | 2015-01-30 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| RS61937B1 (sr) * | 2016-08-05 | 2021-07-30 | Boehringer Ingelheim Int | Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat) |
-
2019
- 2019-01-28 MX MX2020008116A patent/MX2020008116A/es unknown
- 2019-01-28 PE PE2020001163A patent/PE20210175A1/es unknown
- 2019-01-28 EP EP19702085.2A patent/EP3746450B1/en active Active
- 2019-01-28 JO JOP/2020/0191A patent/JOP20200191A1/ar unknown
- 2019-01-28 CR CR20200331A patent/CR20200331A/es unknown
- 2019-01-28 WO PCT/EP2019/051993 patent/WO2019149659A1/en not_active Ceased
- 2019-01-28 KR KR1020207025418A patent/KR20200118124A/ko not_active Withdrawn
- 2019-01-28 US US16/966,489 patent/US11319310B2/en active Active
- 2019-01-28 EA EA202091804A patent/EA202091804A1/ru unknown
- 2019-01-28 SG SG11202006300XA patent/SG11202006300XA/en unknown
- 2019-01-28 BR BR112020014320-0A patent/BR112020014320A2/pt not_active Application Discontinuation
- 2019-01-28 AU AU2019215709A patent/AU2019215709A1/en not_active Abandoned
- 2019-01-28 CA CA3087827A patent/CA3087827A1/en not_active Abandoned
- 2019-01-28 CN CN201980010384.6A patent/CN111655699B/zh active Active
- 2019-01-28 MA MA053074A patent/MA53074A/fr unknown
- 2019-01-28 JP JP2020541870A patent/JP7150032B2/ja active Active
-
2020
- 2020-07-19 IL IL276137A patent/IL276137A/en unknown
- 2020-07-21 CL CL2020001908A patent/CL2020001908A1/es unknown
- 2020-07-24 CO CONC2020/0009179A patent/CO2020009179A2/es unknown
- 2020-07-31 PH PH12020551169A patent/PH12020551169A1/en unknown
- 2020-08-24 EC ECSENADI202050791A patent/ECSP20050791A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020009179A2 (es) | 2020-07-31 |
| KR20200118124A (ko) | 2020-10-14 |
| CL2020001908A1 (es) | 2020-10-30 |
| US11319310B2 (en) | 2022-05-03 |
| CN111655699B (zh) | 2023-07-14 |
| MA53074A (fr) | 2021-05-12 |
| CN111655699A (zh) | 2020-09-11 |
| WO2019149659A1 (en) | 2019-08-08 |
| ECSP20050791A (es) | 2020-09-30 |
| PH12020551169A1 (en) | 2021-05-31 |
| EP3746450B1 (en) | 2022-03-16 |
| EP3746450A1 (en) | 2020-12-09 |
| AU2019215709A1 (en) | 2020-07-16 |
| JOP20200191A1 (ar) | 2020-07-29 |
| PE20210175A1 (es) | 2021-01-29 |
| SG11202006300XA (en) | 2020-07-29 |
| BR112020014320A2 (pt) | 2020-12-08 |
| EA202091804A1 (ru) | 2020-12-24 |
| CA3087827A1 (en) | 2019-08-08 |
| IL276137A (en) | 2020-09-30 |
| JP7150032B2 (ja) | 2022-10-07 |
| JP2021512112A (ja) | 2021-05-13 |
| US20210040077A1 (en) | 2021-02-11 |
| CR20200331A (es) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551170A1 (en) | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| PH12020551169A1 (en) | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| PH12019500254A1 (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| MX2020008053A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2021005311A (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock). | |
| MY200800A (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
| PH12020550442A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| NZ718373A (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor | |
| EA033236B1 (ru) | Новые производные пиразола в качестве ингибиторов nik | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| JOP20220125A1 (ar) | مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| TN2010000608A1 (en) | Heteroaryl derivatives as dgat1 inhibitors |